These 10 domestic blockbuster drugs have sold best in the past three years
With the coming Oil & Gas Asia Exhibition in Pakistan, ECHEMI rolls out a new bulk purchasing activity for its new and old customers. This activity will be valid before March 16 when the exhibition come to the end. The more you buy, the more money you will save.
How to join this bulk purchasing?
You can enjoy the most favorable prices via three steps:
First, you should come to the home page of ECHEMI, then you can see the the following page:
Second, input your demand and submit the inquiry.
Third, ECHEMI will give you a reply within 1 working day after receiving your inquiry.
Opportunity knocks but once! Come on, seize this opportunity right now!
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-06-19
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Top 10 blockbuster drugs with patents expiring in 2020
-
Lilly’s Indiana Investment Puts API Capacity at the Center of Obesity Drug Competition
-
BASF’s Price Increase Shows Pharma Excipients Are Still Exposed to Chemical Cost Pressure
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
Sun Pharma Halts US Expansion Amid 25 Percent Tariff Threat Net Profit Drops 20 Percent
-
Mounjaro Reduces Heart Events by 8 Percent More Than Trulicity in 13,000-Patient Diabetes Trial
-
JB Pharma Q1 Net Profit Surges 14 Percent to ₹202 Crore Revenue Hits ₹1094 Crore with 30 Percent EBITDA Margin
-
Trump Pressures 17 Pharma CEOs to Match US Drug Prices with Global Lows September 29 Deadline Set
-
Bayer Sets Aside $1.37 Billion for Roundup Lawsuits Raises 2025 Sales Forecast to €48 Billion
-
Moderna to Cut 10 Percent of Staff as COVID Vaccine Sales Plunge Stock Drops 4 Percent
Recommend Reading
-
Mounjaro Usage Doubles in June Sales Surge by 18 in India
-
After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition
-
Betting on Next-Generation Metabolic Therapies: Pfizer’s Big Wager on Metsera and Its Strategic Reshaping in China
-
Merck Nears Acquisition of Cidara to Strengthen Flu Prevention Arsenal
-
Small Pharma Firms Under Threat as Regulator Tightens Quality Norms
-
This Week's Styrene Market Fluctuates and Declines (3.30-4.3)
-
BDO market trend continues to rise in China
-
Ethanol Market Prices at High Levels with Consolidation
-
MTBE Market Trends: First Rise, Then Fall
-
Bullish Factors Remain, April Adipic Acid Prices in China Expected to Rise